Penn Study Links 4-Month Stop-Start Semaglutide Use to Weight Gain as Efficacy Fades in Mice
Updated
Updated · WPVI-TV · May 15
Penn Study Links 4-Month Stop-Start Semaglutide Use to Weight Gain as Efficacy Fades in Mice
5 articles · Updated · WPVI-TV · May 15
A University of Pennsylvania study found mice cycled on and off semaglutide over 4 months gained fat and showed weaker response when the drug was restarted.
Researchers said the loss of effect persisted even after the mice returned to continuous treatment for 62 days, suggesting therapeutic resistance after interruption.
The finding matters because GLP-1 use is widespread—about 1 in 8 adults have used the drugs for weight loss—and more than half discontinue within 2 years before often restarting.
Doctors said GLP-1 weight loss typically comes from roughly 60% fat and 40% muscle, and warned stop-start use in people could produce similar problems, though the new data are from mice.
Can restarting popular weight loss drugs permanently ruin their effectiveness for you?
A new pill could let you keep weight off after stopping Ozempic. How does it work?
Weight Regain After GLP-1 Discontinuation: New Therapies, Mechanisms, and Sustainable Management
Overview
As the medical community refines long-term weight management strategies, new approaches are emerging to help prevent weight regain after stopping GLP-1 medications. These innovative strategies, such as the investigational oral therapy TIX100, target key metabolic pathways by inhibiting TXNIP and aim to protect beta-cell function, improve glucose control, and manage related metabolic conditions. Together, these developments offer hope for more sustained weight management results, addressing the underlying mechanisms that contribute to weight regain and supporting individuals in maintaining their health after discontinuing GLP-1 therapy.